Operating
Stock-Based Comp
Regeneron Pharmaceuticals Stock-Based Comp increased by 3.2% to $257.40M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 0.7%, from $255.70M to $257.40M. Over 4 years (FY 2021 to FY 2025), Stock-Based Comp shows an upward trend with a 13.4% CAGR.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryEfficiency
SignalContext dependent
VolatilityStable
First reportedQ1 2013
Last reportedQ1 2026Apr 29, 2026
How to read this metric
Increasing levels may indicate a focus on talent retention but can also signal potential shareholder dilution.
Detailed definition
This represents the value of equity-based awards granted to employees as part of their total compensation package. Since...
Peer comparison
Standard across large-cap corporations; varies based on corporate compensation philosophy.
Metric ID:
stock_based_compensationHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $145.50M | $136.90M | $188.40M | $166.90M | $159.80M | $166.30M | $232.00M | $238.70M | $202.00M | $203.90M | $240.40M | $230.10M | $223.20M | $225.10M | $304.40M | $255.70M | $251.70M | $237.00M | $249.30M | $257.40M |
| QoQ Change | — | -5.9% | +37.6% | -11.4% | -4.3% | +4.1% | +39.5% | +2.9% | -15.4% | +0.9% | +17.9% | -4.3% | -3.0% | +0.9% | +35.2% | -16.0% | -1.6% | -5.8% | +5.2% | +3.2% |
| YoY Change | — | — | — | — | +9.8% | +21.5% | +23.1% | +43.0% | +26.4% | +22.6% | +3.6% | -3.6% | +10.5% | +10.4% | +26.6% | +11.1% | +12.8% | +5.3% | -18.1% | +0.7% |
Range$136.90M – $304.40M
CAGR+12.8%
Avg YoY Growth+12.9%
Median YoY Growth+10.8%
Current Streak2 quarters growth
Stock-Based Comp at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's stock-based comp?
- Regeneron Pharmaceuticals (REGN) reported stock-based comp of $257.40M in Q1 2026.
- How has Regeneron Pharmaceuticals's stock-based comp changed year-over-year?
- Regeneron Pharmaceuticals's stock-based comp increased by 0.7% year-over-year, from $255.70M to $257.40M.
- What is the long-term trend for Regeneron Pharmaceuticals's stock-based comp?
- Over 4 years (2021 to 2025), Regeneron Pharmaceuticals's stock-based comp has grown at a 13.4% compound annual growth rate (CAGR), from $601.70M to $993.70M.
- What does stock-based comp mean?
- The non-cash cost of paying employees with company stock instead of cash.